Vacc-4x

immunotherapy candidate composed of four modified peptides corresponding to conserved domains of the HIV-1 protein p24 that preferentially include HLA-A2 restricted elements

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Kvale, Dag: 5 articles (09/2013 - 09/2004)
2.	Sørensen, Birger: 5 articles (09/2013 - 09/2004)
3.	Baksaas, Ingebjørg: 4 articles (09/2013 - 09/2004)
4.	Kran, Anne-Marte B: 3 articles (11/2010 - 09/2004)
5.	Sommerfelt, Maja A: 3 articles (11/2010 - 09/2004)
6.	Lind, Andreas: 2 articles (09/2013 - 08/2012)
7.	Sommerfelt, Maja: 2 articles (09/2013 - 08/2012)
8.	Bruun, Johan N: 2 articles (07/2005 - 09/2004)
9.	Nyhus, Jørgen: 2 articles (07/2005 - 09/2004)
10.	Aass, Hans Christian D: 1 article (09/2013)

Related Diseases

1.	Hypersensitivity (Allergy) 08/01/2012 - "Proliferation correlated with the Vacc-4x delayed-type hypersensitivity test (DTH) obtained after completed immunizations (CD4 + r = 0.63 (p = 0.002) and CD8 + r = 0.47 (p = 0.03)), suggesting that they represent T cell memory recall responses. " 07/01/2005 - "Patients with the highest delayed type hypersensitivity (DTH) responses to Vacc-4x-peptides before treatment interruption tended to achieve lower actual HIV RNA levels at the end of the study compared to Vacc-4x DTH low-responders (p=0.08) and significantly so in terms of viral loads relative to their individual pre-HAART HIV RNA set-points (p=0.04). " 09/23/2013 - "Vacc-4x T cell responses were measured by proliferation (CFSE), INF-γ, CD107a, Granzyme B, Delayed-Type Hypersensitivity test (DTH) and cytokines and chemokines (Luminex). "
2.	HIV Infections (HIV Infection) 08/01/2010 - "Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection."
3.	Viremia 11/13/2010 - "The overall rate of amino acid substitutions was low during 35 months (median) of postimmunization viremia, with similar rates of substitution within the regions corresponding to Vacc-4x peptides and other p24 regions despite durable Vacc-4x-specific T-cell responses. "
4.	Acquired Immunodeficiency Syndrome (AIDS) 09/24/2004 - "Non-AIDS, HIV-1 infected healthy patients (n = 40) stable on HAART with CD4 counts > 300 x 10 cells/l were randomized to receive either low-dose or high-dose Vacc-4x over 26 weeks in an open, prospective phase II clinical trial. "

Related Drugs and Biologics

1.	RNA (Ribonucleic Acid)
2.	Peptides (Polypeptides)
3.	Granzymes (Granzyme)
4.	Chemokines
5.	Cytokines
6.	Vaccines
7.	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)